Bexarotene
Primary Cutaneous Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.Small moleculePhase 3Dormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Primary Cutaneous Anaplastic Large Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin John Reneau | Phase 3 | BB |
METHOTREXATE Millennium Pharmaceuticals, Inc. | Phase 3 | BB |
cc-5013 John Reneau | Phase 2 | B |
Pralatrexate Acrotech Biopharma Inc. | Phase 1 | CC |
Gm-Csf Medical College of Wisconsin | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Bexarotene is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →